Potential role of TCF7L2 gene variants on cardiac sympathetic/ parasympathetic activity

European Journal of Human Genetics

Volumn 18, Issue 12, 2010, Pages 1333-1338

  Boccardi, Virginia ^a   Ambrosino, Immacolata ^a   Papa, Michela ^a   Fiore, Daniela ^a   Rizzo, Maria Rosaria ^a   Paolisso, Giuseppe ^a   Barbieri, Michelangela ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

cardiac electrophisiology; gene polymorphism; glucose metabolism

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; TRANSCRIPTION FACTOR 7 LIKE 2;

ADULT; AREA UNDER THE CURVE; ARTICLE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART FUNCTION; HEART RATE VARIABILITY; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PARASYMPATHETIC FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; SYMPATHETIC FUNCTION; VAGUS NERVE;

ADULT; ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; FEMALE; GENOTYPE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HEART; HUMANS; INSULIN; LINEAR MODELS; MALE; PARASYMPATHETIC NERVOUS SYSTEM; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; SYMPATHETIC NERVOUS SYSTEM; TRANSCRIPTION FACTOR 7-LIKE 2 PROTEIN; YOUNG ADULT;

RATTUS;

EID: 78549272005     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.117     Document Type: Article

References (36)

1. Jin T, Liu L: The Wnt signalling pathway effector TCF7L2 and type II diabetes mellitus. Mol Endocrinol 2008; 22: 2383-2392.
2. Yu M, Moreno C, Hoagland KM et al: Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-1135.
3. Grant SF, Thorleifsson G, Reynisdottir I et al: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006; 38: 320-323.
4. Groves CJ, Zeggini E, Minton J et al: Association analysis of 6736 U.K. subjects provides replication and confirms TCF7L2 as a type 2 diabetes susceptibility gene with a substantial effect on individual risk. Diabetes 2006; 55: 2640-2644.
5. Florez JC, Jablonski KA, Bayley N et al: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 2006; 355: 241-250.
6. Damcott CM, Pollin TI, Reinhart LJ et al: Polymorphisms in the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in the Amish: replication and evidence for a role in both insulin secretion and insulin resistance. Diabetes 2006; 55: 2654-2659.
7. Saxena R, Gianniny L, Burtt NP et al: Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006; 55: 2890-2895.
8. Zhang C, Qi L, Hunter DJ et al: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes 2006; 55: 2645-2648.
9. Cauchi S, Meyre D, Dina C et al: Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes. Diabetes 2006; 55: 2903-2908.
10. Scott LJ, Bonnycastle LL, Willer CJ et al: Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006; 55: 2649-2653.
11. Schafer SA, Tscritter O, Machicao F et al: Impaired glucagons-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007; 50: 2443-2450.
12. Nystrom T, Gutniak MK, Zhang Q et al: Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: 1209-1215.
13. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M: Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
14. Merchenthaler I, Lane M, Shughrue P: Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999; 403: 261-280.
15. Wei Y, Mojsov S: Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 219-224.
16. Yamamoto H, Lee CE, Marcus JN et al: Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110: 43-52.
17. Yamamoto H, Kishi T, Lee CE et al: Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003; 23: 2939-2946.
18. Bharucha AE, Charkoudian N, Andrews CN et al: Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008; 295: 874-880.
19. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology Heart rate variability: Standards of measurements, physiological interpretation, and clinical use. Eur Heart J 1996; 17: 354-381.
20. Malliani A, Lombardi F, Pagani M, Cerutti S: Cardiovascular neural regulation explored in the frequency domain. Circulation 1991; 84: 1482-1492.
21. Paolisso G, Manzella D, Ferrara N et al: Glucose ingestion affects cardiac ANS in healthy subjects with different amounts of body fat. Am J Physiol 1997; 273: 471-478.
22. Paolisso G, Manzella D, Tagliamonte MR, Rizzo MR, Gambardella A, Varricchio M: Effects of different insulin infusion rates on heart rate variability in lean and obese subjects. Metabolism 1999; 48: 755-762.
23. Aberti KGMM, Zimmet PZ, for the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of WHO consultation. Diab Med 1998; 15: 539-553.
24. Kleiger RE, Stein PK, Bigger Jr JT: Heart rate variability: measurement and clinical utility. Ann Noninvasive Electrocardiol 2005; 10: 88-101.
25. Jonsen SJ, Andersen N: On power estimation in maximum entropy spectral analysis. Geophysics 1978; 43: 681-690.
26. Yi F, Brubaker PL, Jin T: TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem 2005; 280: 1457-1464.
27. Fehmann HC, Goke R, Goke B: Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 1995; 16: 390-410.
28. Seals DR, Bell C: Chronic sympathetic activation: consequence and cause of age-associated obesity? Diabetes 2004; 53: 276-284.
29. van Baak Marlen A: Meal-induced activation of sympathetic nervous system and its cardiovascular and thermogenic effects in man. Physiol Behav 2007; 94: 178-186.
30. Tsuji H, Venditti Jr FJ, Manders ES et al: Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994; 90: 878-883.
31. Mancia G, Bousquet P, Elghozi JL et al: The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007; 25: 909-920.
32. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnorm-alities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
33. Berne C, Fagius J, Pollare T, Hjemdahl P: The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 1992; 35: 873-879.
34. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87: 2246-2252.
35. Schroeder EB, Chambless LE, Liao D et al: Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2005; 28: 668-674.
36. Manzella D, Paolisso G: Cardiac autonomic activity and type II diabetes mellitus. Clinical Science 2005; 108: 93-99.